Develop scalable prototype of new and effective 5-strain probiotic for IBS
| Reference number | |
| Coordinator | Immunebiotech Medical Sweden AB |
| Funding from Vinnova | SEK 609 250 |
| Project duration | June 2018 - April 2019 |
| Status | Completed |
Purpose and goal
Overall goal: Meeting the huge unmeet need for IBS by providing an effective probiotic product, GutMagnific. IBS is affecting 10-15% of the population. It’s a disorder of the digestive tract causing pain, bloating, constipation and/or diarrhea, and often associated with depression. Current probiotic products are developed primarily to be easy to produce rather than to have beneficial biological effects. Aim: GutMagnific is a scientifically designed 5-strain probiotic product with verified effects in experimental models and in a pilot clinical trial and will be launched in 2019.
Expected results and effects
Results obtained 1) Commercial scale production processes for fermentation and freeze drying in place for the 5-strains. Adapted to yield cost effective production with high yield of live bacteria. Now ready to order first commercial batches. 2) Prototype of product in oral capsules ready for use in clinical study trials as food supplement 3) Business plan in place for market launch of GutMagnificTM in 2019 with brand strategy and evaluation of regulatory aspects.
Planned approach and implementation
WP 1 Process development Together with partner Sacco we have developed a scalable production process for each of the 5 strains. Analysis: Conducted according to plan and goals reached WP 2 Prototype Together with Nutrilinea we have formulated the prototype in gastro resistant capsules Analysis: Some time delays and goals reached WP3) Business plan Business plan according to plan in place for market launch in 2019. Analysis: Changed parter to The Health Marketing Team, expert in brand strategy, to support with product branding and preparation for commercial launch.